Bone marrow micrometastasis in breast cancer: Review of detection methods, prognostic impact and biological issues

Journal of Clinical Pathology

Volumn 61, Issue 5, 2008, Pages 570-576

  Vincent Salomon, A ^a   Bidard, F C ^a   Pierga, J Y ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW BIOPSY; BONE MARROW METASTASIS; BREAST CANCER; CANCER STEM CELL; DISSEMINATED CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MICROMETASTASIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; REVIEW; TUMOR CELL;

BONE MARROW EXAMINATION; BONE MARROW NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM CIRCULATING CELLS; NEOPLASTIC STEM CELLS; PROGNOSIS;

EID: 43549083683     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.046649     Document Type: Review

References (97)

1. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
2. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
3. Fehm T, Braun S, Muller V, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006;107:885-92.
4. Wiedswang G, Borgen E, Karesen R, et al. Detection of isolated tumor cells in BM from breast-cancer patients: significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analyzed. Cytotherapy 2003;5:40-5.
5. Naume B, Wiedswang G, Borgen E, et al. The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells. Clin Cancer Res 2004;10:3091-7.
6. Borgen E, Naume B, Nesland JM, et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood. I: Establishment of objective criteria for the evaluation of immunostained cells. The European ISHAGE Working Group for Standardization of Tumor Cell Detection. Cytotherapy 1999;1:377-88.
7. Borgen E, Pantel K, Schlimok G, et al. A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow. Cytometry B Clin Cytom 2006;70:400-9.
8. Bidard FC, Vincent-Salomon A, Gomme S, et al. Bone marrow micrometastasis are a powerful prognostic factor in stage I to III breast cancer patients. Abstract S460. AACR Annual Meeting, Proceedings, 14-18 April 2007.
9. Schardt JA, Meyer M, Hartmann CH, et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 2005;8:227-39.
10. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 2003;100:7737-42.
11. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342:525-33.
12. Mansi JL, Gogas H, Bliss JM, et al. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999;354:197-202.
13. Ring A, Smith IE, Dowsett M. Circulating tumour cells in breast cancer. Lancet Oncol 2004;5:79-88.
14. Naume B, Borgen E, Kvaheim G, et al. Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics. Clin Cancer Res 2001;7:4122-9.
15. de Crémoux P, Extra JM, Denis MG, et al. Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin Cancer Res 2000;6:3117-22.
16. Pierga JY, Bonneton C, Magdelenat H, et al. Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int J Cancer 2005;114:291-8.
17. Ferrucci PF, Rabascio C, Gigli F, et al. A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer. Int J Oncol 2007;30:955-62.
18. Vincent-Salomon A, Pierga JY, Couturier J, et al. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer 2007;96:654-9.
19. Slade MJ, Coombes RC. The clinical significance of disseminated tumor cells in breast cancer. Nat Clin Pract Oncol 2007;4:30-41.
20. Gerber B, Krause A, Muller H, et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 2001;19:960-71.
21. Gebauer G, Fehm T, Merkle E, et al. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001;19:3669-74.
22. Braun S, Pantel K. Clinical significance of occult metastatic cells in bone marrow of breast cancer patients. Oncologist 2001;6:125-32.
23. Zach O, Lutz D. Tumor cell detection in peripheral blood and bone marrow. Curr Opin Oncol 2006;18:48-56.
24. Muller V, Hayes DF, Pantel K. Recent translational research: circulating tumor cells in breast cancer patients. Breast Cancer Res 2006;8:110.
25. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
26. Cristofanilli M, Broglio KR, Guarneri V, et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer 2007;7:471-9.
27. Ignatiadis M, Xenidis N, Perraki M, et al. Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 2007;25:5194-202.
28. Cristofanilli M, Mendelsohn J. Circulating tumor cells in breast cancer: advanced tools for "tailored" therapy? Proc Natl Acad Sci USA 2006;103:17073-4.
29. Muller V, Stahmann N, Riethdorf S, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005;11:3678-85.
30. Pierga JY, Bonneton C, Vincent-Salomon A, et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 2004;10:1392-400.
31. Benoy IH, Elst H, Philips M, et al. Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer. Clin Breast Cancer 2006;7:146-52.
32. Wiedswang G, Borgen E, Schirmer C, et al. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer 2005;118:2013-9.
33. Janni W, Rack B, Schindlbeck C, et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 2005;103:884-91.
34. Wiedswang G, Borgen E, Karesen R, et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 2004;10:5342-8.
35. Slade MJ, Singh A, Smith BM, et al. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. Int J Cancer 2005;114:94-100.
36. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relet Cancer 2006;13:1033-67.
37. Quintela-Fandino M, Lopez JM, Hitt R, et al. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. J Clin Oncol 2006;24:3611-8.
38. Braun S, Kentenich C, Janni W, et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000;18:80-6.
39. Braun S, Hepp F, Kentenich CR, et al. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 1999;5:3999-4004.
40. Bozionellou V, Mavroudis D, Perraki M, et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004;10:8185-94.
41. Allan AL, Vantyghem SA, Tuck AB, et al. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis 2006;26:87-98.
42. Townson JL, Chambers AF. Dormancy of solitary metastatic cells. Cell Cycle 2006;5:1744-50.
43. Wiedswang G, Borgen E, Karesen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003;21:3469-78.
44. Gangnus R, Langer S, Breit E, et al. Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res 2004;10:3457-64.
45. Kollermann J, Muller M, Goessl C, et al. Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients. Eur Urol 2003;44:533-8.
46. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
47. Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 2006;25:573-87.
48. Kaifi JT, Yekebas EF, Schurr P, et al. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005;97:1840-7.
49. Holland JD, Kochetkova M, Akekawatchai C, et al. Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells. Cancer Res 2006;66:4117-24.
50. Peng SB, Peek V, Zhai Y, ef al. Akt activation, but not extracellular signal-regulated kinase activation, is required for SDF-1alpha/CXCR4-mediated migration of epitheloid carcinoma cells. Mol Cancer Res 2005;3:227-36.
51. Sun Y, Cheng Z, Ma L, et al. Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem 2002;277:49212-9.
52. Andre F, Cabioglu N, Assi H, et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2006;17:945-51.
53. Kallergi G, Mavroudis D, Georgoulias V, et al. Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 2007;13:79-88.
54. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005;11:8006-14.
55. Benoy IH, Salgado R, Eist H, et al. Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res 2005;7:R210-9.
56. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989;8:98-101.
57. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
58. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
59. Suzuki M, Mose ES, Montel V, et al. Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am J Pathol 2006;169:673-81.
60. Putz E, Witter K, Offner S, et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 1999;59:241-8.
61. Pierga JY, Bonneton C, Magdelenat H, et al. Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer. Br J Cancer 2003;89:539-45.
62. Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-62.
63. Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002;360:683-9.
64. Jenkins DE, Hornig YS, Oei Y, et al. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 2005;7:R444-54.
65. Kurebayashi J, McLeskey SW, Johnson MD, et al. Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ. Cancer Res 1993;53:2178-87.
66. Naumov GN, MacDonald IC, Weinmeister PM, et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 2002;62:2162-8.
67. Yuhas JM, Tarleton AE. Dormancy and spontaneous recurrence of human breast cancer in vitro. Cancer Res 1978;38(11 Pt 1):3584-9.
68. Koran R, Boots M, Wieder R. Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res 2004;64:4514-22.
69. Klein CA, Holzel D. Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle 2006;5:1788-98.
70. Demicheli R, Miceli R, Moliterni A, et al. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol 2005;16:1449-57.
71. Aguirre-Ghiso JA. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 2002;21:2513-24.
72. Aguirre-Ghiso JA, Estrada Y, Liu D, et al. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003;63:1684-95.
73. Wicha MS. Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res 2006;12:5606-7.
74. Vaidya JS. An alternative model of cancer cell growth and metastasis. Int J Surg 2007;5:73-5.
75. Brabletz T, Jung A, Spaderna S, et al. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5:744-9.
76. Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006;12:5615- 21.
77. Hill A, McFarlane S, Mulligan K, et al. Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells. Oncogene 2006;25:6079-91.
78. Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24 - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006;8:R59.
79. Redding WH, Coombes RC, Monaghan P, et al. Detection of micrometastases in patients with primary breast cancer. Lancet 1983;2:1271-4.
80. Manegold C, Krempien B, Kaufmann M, et al. The value of bone marrow examination for tumor staging in breast cancer. J Cancer Res Clin Oncol 1988;114:425-8.
81. Landys K, Persson S, Kovarik J, et al. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: results of a 20-year median follow-up. Breast Cancer Res Treat 1998;49:27-33.
82. Salvadori B, Squicciarini P, Rovini D, et al. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur J Cancer 1990;26:865-7.
83. Mathieu MC, Friedman S, Bosq J, et al. Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer. Breast Cancer Res Treat 1990;15:21-6.
84. Kirk SJ, Cooper GG, Hoper M, et al. The prognostic significance of marrow micrometastases in women with early breast cancer. Eur J Surg Oncol 1990;16:481-5.
85. Singletary SE, Larry L, Tucker SL, et al. Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients. J Surg Oncol 1991;47:32-6.
86. Cote RJ, Rosen PP, Lesser ML, et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9:1749-56.
87. Schlimok G, Lindemann F, Holzmann K, et al. Prognostic significance of disseminated tumor cells detected in bone marrow of patients with breast and colorectal cancer: a multivariate analysis. Abstract 102. Proc Am Soc Clin Oncol 1992;11.
88. Harbeck N, Unten M, Pache L, et al. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 1994;69:566-71.
89. Menard S, Squicciarini P, Luini A, et al. Immunodetection of bone marrow micrometastases in breast carcinoma patients and its correlation with primary tumour prognostic features. Br J Cancer 1994;69:1126- 9.
90. Molino A, Pelosi G, Turazza M, et al. Bone marrow micrometastases in 109 breast cancer patients: correlations with clinical and pathological features and prognosis. Breast Cancer Res Treat 1997;42:23-30.
91. Funke I, Fries S, Rolle M, et al. Comparative analyses of bone marrow micrometastases in breast and gastric cancer. Int J Cancer 1996;65:755-61.
92. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996;88:1652-8.
93. Solomayer EF, Diel IJ, Salanti G, et al. Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res 2001;7:4102-8.
94. Berger U, Bettelheim R, Mansi JL, et al. The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol 1988;90:1-6.
95. Lyda MH, Tetef M, Carter NH, et al. Keratin immunohistochemistry detects clinically significant metastases in bone marrow biopsy specimens in women with lobular breast carcinoma. Am J Surg Pathol 2000;24:1593-9.
96. Untch M, Kahlert S, Funke I, et al. Detection of cytokeratin (CK) 18 positive cells in the bone marrow (BM) of breast cancer patients-no prediction of bad outcome. (Abstract 2472). Proc Am Soc Clin Oncol 1999;18:693a.
97. Kasimir-Bauer S, Oberhoff C, Sliwinska K, et al. Evaluation of different methods for the detection of minimal residual disease in blood and bone marrow of patients with primary breast cancer: importance for clinical use? Breast Cancer Res Treat 2001;69:123-32.